Development of angle-resolved low coherence interferometry for clinical detection of dysplasia.
Development of angle-resolved low coherence interferometry for clinical detection of dysplasia.
复制标题
DOI：
10.4103/1477-3163.83935
复制
发表时间：
2011
影响因子：
--
通讯作者：
Wax A
中科院分区：
文献类型：
--
作者：
Zhu Y;Terry NG;Wax A
本文综述了角度分辨低相干干涉术（a/LCI）从最初的发展到临床应用的发展。在第一个应用中，该方法使用了时域干涉测量方案，并使用致癌动物模型进行了验证，以评估原位检测发育异常的可行性。该方法的进一步发展导致了具有更高通量和内窥镜兼容探针的傅立叶域干涉测量方案，以实现临床应用。这些后来的实施方案已被应用于巴雷特食管组织中发育不良的临床研究，巴雷特食管组织是一种与食管腺癌风险增加相关的化生组织类型。作为系统性活检的替代方法，a/LCI方法提供了检测这些组织中异型增生的高灵敏度和特异性，同时避免了组织切除或外源性造影剂的需要。在这里，/LCI的各种实现进行了讨论，并初步的动物实验和离体人体组织研究的结果进行了审查。还介绍了最近的体内临床研究的综述。
This review covers the development of angle-resolved low coherence interferometry (a/LCI) from initial development through clinical application. In the first applications, the approach used a time-domain interferometry scheme and was validated using animal models of carcinogenesis to assess the feasibility of detecting dysplasia in situ. Further development of the approach led to Fourier-domain interferometry schemes with higher throughput and endoscope-compatible probes to enable clinical application. These later implementations have been applied to clinical studies of dysplasia in Barrett's esophagus tissues, a metaplastic tissue type that is associated with an increased risk of esophageal adenocarcinoma. As an alternative to systematic biopsy, the a/LCI approach offers high sensitivity and specificity for detecting dysplasia in these tissues while avoiding the need for tissue removal or exogenous contrast agents. Here, the various implementations of a/LCI are discussed and the results of the preliminary animal experiments and ex vivo human tissue studies are reviewed. A review of a recent in vivo clinical study is also presented.